Under the terms of the agreement, CiVentiChem will provide research services in the areas of medicinal chemistry, custom compound synthesis and process development. Both CiVentiChem US facility and its subsidiary, Indus Biosciences, located in India will facilitate the development.
CiVentiChem will apply its manufacturing and development expertise to the goal of accelerating the progress of Tranzyme’s novel small molecule products for the treatment of post-operative ileus, gastroparesis, and other gastrointestinal (GI) disorders. Financial details of the agreement were not disclosed.
“CiVentiChem offers us a unique advantage by leveraging extensive chemistry expertise in India through its operations in Hyderabad,” said Mark Peterson, vice president of operations for Tranzyme Pharma. “We look forward to their continued involvement in our drug development programs.”